Bevespi Aerosphere approved in the EU for COPD
20 December 2018 13:45 GMT Bevespi Aerosphere approved in the EU for chronic obstructive pulmonary disease AstraZeneca today announced that the European Commission (EC) has approved Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in a pressurised metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere is the first medicine in its class to be approved by the EC in a pMDI. The approval offers patients with COPD an important new choice of inhaler device.